Tag: VIVA

New data reconfirm long-term safety profile of the Philips Stellarex low-dose...

Royal Philips recently announced the four-year results from the ILLUMENATE European randomised controlled trial (EU RCT). The Stellarex drug-coated balloon (DCB) cohort demonstrated similar...
tack

Intact Vascular announces positive one-year data from TOBA II BTK clinical...

Intact Vascular announced the positive one-year results from its Tack optimised balloon angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA)...

VIVA Physicians publishes analysis evaluating mortality and paclitaxel-coated devices

An individual patient-level data (IPD) analysis of the safety of paclitaxel-containing devices (PTXD), conducted by VIVA Physicians, identified an absolute 4.6% increased mortality risk...

Virtual VIVA roundtable addresses COVID-19 pandemic

VIVA Physicians recently hosted a virtual roundtable to address COVID-19. Tony Das (Connected Cardiovascular Care Associates, Dallas and BSW Heart Hospital, Plano, USA), one...

Vascular Leaders Forum discussions seek consensus on paclitaxel

The Vascular Leaders Forum (VLF, 1–2 March, Washington DC, USA), hosted by the non-profit organisation VIVA Physicians, is a special consortium which was called...

Lutonix 014 DCB gathers first randomised evidence of positive safety and...

Six-month outcomes of the Lutonix BTK IDE trial, a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (DCB; BD), has demonstrated that...

Lutonix Global Real-World Registry 24-month outcomes presented at VIVA 2016

Bard has announced the presentation of the final 24-month results from the Lutonix Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 meeting...

Positive late-breaking DANCE clinical trial data presented at VIVA 2016

Christopher Owens, associate professor of Surgery in the Division of Vascular and Endovascular Surgery at the University of California, San Francisco (UCSF), USA, has...

Medtronic Valiant Captivia demonstrates safety and efficacy at three years

Medtronic has announced new data, demonstrating safety and efficacy at three years in acute complicated type B aortic dissection patients treated with the Valiant Captivia thoracic...

One-year Japanese results support use of the Viabahn endoprosthesis to treat...

Gore has announced positive results from a prospective, multicentre investigational device exemption (IDE) clinical study of the Viabahn endoprosthesis with heparin bioactive surface in...

Endologix reports positive clinical data from Ovation LIFE study

Endologix has announced positive clinical data from the Ovation LIFE (Least Invasive Fast-Track EVAR) study. Zvonimir Krajcer, co-director, Peripheral Vascular Disease Service at Texas...